Treatment of Prostate Cancer by Targeting Vascular Endothelial Growth Factor Receptors (VEGFRs) and Micrometastases with Bismuth-213 Labeled Vectors; Final rept. 5 Oct 2005-4 Oct 2007

摘要

The main purpose of the proposed study was to evaluate the toxicity and efficacy of multiple targeting vectors for the treatment of prostate cancer in mouse models. After successfully achieving the in vitro outcomes, the in vivo studies have also proven to be a great success. The efficacy of the proposed combination therapy has proven to be far better than the mono-therapy and the results are significantly different. Various combination therapy regimes were well tolerated in mice whereas the long-term toxicity studies are currently ongoing. The dose optimization, time interval optimization and subcutaneous efficacy studies have been completed whereas orthotopic model studies are expected to be complete in three months. Thus the in vitro (radiolabeling of Avastin, in vitro stability, enhancement of plasminogen activation expression and estimation of VEGF secretion by various prostate cancer cell lines) and in vivo studies have gone as per expectations and plan.